Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial

被引：0
|
作者：
Vaduganathan, M. [1 ]
Sattar, N. [2 ]
Fitchett, D. [3 ]
Ofstad, A. [4 ]
Brueckmann, M. [5 ,6 ]
George, J. T. [5 ]
Verma, S. [3 ]
Mattheus, M. [7 ]
Wanner, C. [8 ]
Inzucchi, S. E. [9 ]
Zinman, B. [10 ]
Butler, J. [11 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[4] Boehringer Ingelheim KS, Asker, Norway
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Heidelberg Univ, Mannheim, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[8] Univ Hosp Wurzburg, Wurzburg, Germany
[9] Yale Univ, Sch Med, Yale New Haven Hosp, New Haven, CT USA
[10] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada
[11] Univ Mississippi, Jackson, MS 39216 USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
572
引用
收藏
页码：S275 / S275
页数：1
相关论文
共 50 条
  • [21] Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Hantel, Stefan
    Woerle, Hans-Juergen
    Broedl, Uli C.
    von Eynatten, Maximilian
    Groop, Per-Henrik
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (11): : 2755 - 2769
  • [22] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
    Jurisic-Erzen, D.
    Johansen, O.
    George, J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    DIABETOLOGIA, 2016, 59 : S349 - S349
  • [23] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    Ferreira, Joao Pedro
    Verma, Subodh
    Fitchett, David
    Ofstad, Anne Pernille
    Lauer, Sabine
    Zwiener, Isabella
    George, Jyothis
    Wanner, Christoph
    Zinman, Bernard
    Inzucchi, Silvio E.
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [24] Improvements in Liver Enzymes with Empagliflozin in the EMPA-REG OUTCOME Trial
    Sattar, Naveed
    Fitchett, David H.
    Hantel, Stefan
    George, Jyothis T.
    Zinman, Bernard
    DIABETES, 2018, 67
  • [25] Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    CIRCULATION, 2020, 142
  • [26] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    João Pedro Ferreira
    Subodh Verma
    David Fitchett
    Anne Pernille Ofstad
    Sabine Lauer
    Isabella Zwiener
    Jyothis George
    Christoph Wanner
    Bernard Zinman
    Silvio E. Inzucchi
    Cardiovascular Diabetology, 19
  • [27] The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
    Kaku, Kohei
    Wanner, Christoph
    Anker, Stefan D.
    Pocock, Stuart
    Yasui, Atsutaka
    Mattheus, Michaela
    Lund, Soren S.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 662 - 674
  • [28] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    Lund, S. S.
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Fitchett, D.
    DIABETOLOGIA, 2018, 61 : S324 - S325
  • [29] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Lund, S. S.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1091 - 1091
  • [30] Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME
    Neeland, L. J.
    McGuire, D. K.
    Fernandez, C. S.
    Mattheus, M.
    Woerle, H. -J.
    Johansen, O.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S348 - S348
12345